We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+9.15%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$196M
AUM Growth
+$19.4M
(+11%)
Cap. Flow
+$8.89M
Cap. Flow
% of AUM
4.54%
Top 10 Holdings %
Top 10 Hldgs %
46.87%
Holding
69
New
3
Increased
33
Reduced
3
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TEAR
TearLab Corporation
TEAR
|
+$4.8M |
| 2 |
Insmed
INSM
|
+$3.7M |
| 3 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$1.94M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$1.86M |
| 5 |
Verastem
VSTM
|
+$1.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanda Pharmaceuticals
VNDA
|
+$3.29M |
| 2 |
SPNC
Spectranetics Corp
SPNC
|
+$2.88M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$2.52M |
| 4 |
Align Technology
ALGN
|
+$2.05M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.63% |
| 2 | Consumer Staples | 0.8% |
| 3 | Financials | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioMarin Pharmaceuticals
BMRN
$11.6B
| $3.07M | 1.57% |
24,606
+2,544
| +12% | +$270K |
|
27
Alkermes
ALKS
$8.22B
| $3.02M | 1.54% |
49,597
-21,264
| -30% | -$1.45M |
|
|
CPHD
28
DELISTED
Cepheid Inc
CPHD
| $2.83M | 1.45% |
49,784
+5,026
| +11% | +$283K |
|
29
STAAR Surgical
STAA
$1.21B
| $2.53M | 1.29% |
340,662
+34,281
| +11% | +$251K |
|
30
LeMaitre Vascular
LMAT
$2.32B
| $2.45M | 1.25% |
292,119
+28,973
| +11% | +$227K |
|
31
HealthStream
HSTM
$819M
| $2.31M | 1.18% |
91,690
+9,245
| +11% | +$252K |
|
32
Vertex Pharmaceuticals
VRTX
$121B
| $2.28M | 1.17% |
19,365
+1,774
| +10% | +$213K |
|
|
AMAG
33
DELISTED
AMAG Pharmaceuticals
AMAG
| $2.22M | 1.14% |
+40,695
| New | +$1.94M |
|
|
BLUE
34
DELISTED
bluebird bio
BLUE
| $2.14M | 1.09% |
1,368
+132
| +11% | +$174K |
|
|
35
Verastem
VSTM
$510M
| $2.12M | 1.08% |
+17,327
| New | +$1.82M |
|
|
STKL
36
DELISTED
SunOpta
STKL
| $1.57M | 0.8% |
147,418
+14,434
| +11% | +$158K |
|
37
Cytokinetics
CYTK
$10.5B
| $1.35M | 0.69% |
199,014
+19,825
| +11% | +$148K |
|
|
PETX
38
DELISTED
Aratana Therapeutics, Inc.
PETX
| $1.03M | 0.53% |
64,206
+6,141
| +11% | +$109K |
|
|
ENDP
39
DELISTED
Endo International plc
ENDP
| $732K | 0.37% |
8,161
| – | – |
|
40
United Therapeutics
UTHR
$25.8B
| $659K | 0.34% |
3,820
| – | – |
|
41
Elevance Health
ELV
$81.5B
| $632K | 0.32% |
4,095
| – | – |
|
42
Humana
HUM
$43.7B
| $630K | 0.32% |
3,540
| – | – |
|
|
AGN
43
DELISTED
Allergan plc
AGN
| $606K | 0.31% |
2,035
| – | – |
|
44
Novartis
NVS
$297B
| $599K | 0.31% |
6,774
| – | – |
|
45
Viatris
VTRS
$20.4B
| $580K | 0.3% |
9,775
| – | – |
|
|
AET
46
DELISTED
Aetna Inc
AET
| $556K | 0.28% |
5,215
| – | – |
|
47
Bristol-Myers Squibb
BMY
$133B
| $535K | 0.27% |
8,290
| – | – |
|
|
CELG
48
DELISTED
Celgene Corp
CELG
| $493K | 0.25% |
4,280
| – | – |
|
49
Becton Dickinson
BDX
$45.6B
| $487K | 0.25% |
3,480
+615
| +21% | +$86.1K |
|
50
Steris
STE
$22.3B
| $445K | 0.23% |
6,330
| – | – |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q1 2015 Portfolio in Review
As of Q1 2015, First Light Asset Management held 69 positions worth $196M, up 11% from $176M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
First Light Asset Management deployed $8.89M of net new capital in Q1 2015, opening 3 new positions and adding to 33 existing holdings. Its largest new stake was Insmed: 210,066 shares worth $4.37M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Consumer Staples and Financials.
On the sell side, the largest reduction was Spectranetics Corp, an estimated $2.88M trimmed.
- First Light Asset Management's largest Q1 2015 buy was Insmed: 210,066 shares worth $4.37M.
- First Light Asset Management added most to TearLab Corporation in Q1 2015, an estimated $4.8M increase.
- First Light Asset Management's biggest Q1 2015 reduction was Spectranetics Corp, cutting an estimated $2.88M.
- First Light Asset Management fully exited Vanda Pharmaceuticals in Q1 2015, selling an estimated $3.29M.
- First Light Asset Management's ten largest holdings make up 47% of its $196M portfolio in Q1 2015.
- First Light Asset Management opened 3 new positions and closed 7 in Q1 2015.
- First Light Asset Management's portfolio value rose 11% quarter-over-quarter to $196M.
Based on First Light Asset Management's 13F filing for Q1 2015, filed 15 May 2015.